Michigan [US], April 13 : The most frequent type of pulmonary fibrosis scarring of the lungs is idiopathic, which means that the cause is unclear.
Researchers are working quickly to develop treatments to prevent or reduce idiopathic pulmonary fibrosis (IPF) and associated lung disorders, which can cause severe shortness of breath, dry cough, and intense exhaustion. The average survival time after being diagnosed with IPF is about three to five years, and there is no cure.
A recent U-M study conducted by Sean Fortier, M.D. and Marc Peters-Golden, M.D. from the Division of Pulmonary and Critical Care Medicine at U-M Medical School, discovered a pathway used during normal wound healing that has the potential to reverse IPF.
Using a mouse model, they simulated IPF by administering bleomycin, a chemotherapy agent that causes cell injury and confirmed that the resulting lung scarring resolved itself over the span of about six weeks.
Because of this, "studying fibrosis is kind of tough," said Fortier. "If we're going to give experimental drugs to try and resolve fibrosis, we have to do it before it resolves on its own.
Otherwise, we will not be able to tell if the resolution was the action of the drug or natural repair mechanisms of the body."
However, he said, "there's actually a lot to learn about how the mouse gets better on its own. If we can learn the molecular mechanisms by which this occurs, we may uncover new targets for IPF."
The process by which lung injury either leads to healing or fibrosis relies in part on what happens to a cell called a fibroblast, which forms connective tissue.
During injury or illness, fibroblasts are activated, becoming myofibroblasts that form scar tissue by secreting collagen. When the job is done, these fibroblasts must be deactivated, or de-differentiated, to go back to their quiet state or undergo programmed cell death and be cleared.
"This is the major distinction between normal wound healing and fibrosis - the persistence of activated myofibroblasts," explained Fortier. That deactivation is controlled by molecular brakes. The study examined one of these brakes, called MKP1 - which the team found was expressed at lower levels in fibroblasts from patients with IPF.
By genetically eliminating MKP1 in fibroblasts of mice after establishing lung injury, the team saw that fibrosis continued uncontrolled.
"Instead of at day 63, seeing that nice resolution, you still see fibrosis," said Fortier.
"We argued by contradiction: when you knock out this brake, fibrosis that would otherwise naturally disappear, persists and therefore MKP1 is necessary for spontaneous resolution of fibrosis."
They performed several additional studies using CRISPR techniques to demonstrate how MKP1 applies the brakes, mainly by deactivating the enzyme p38a, which is implicated in a cell's reaction to stress.
Furthermore, they demonstrated that neither of the two current FDA approved drugs for lung fibrosis, pirfenidone and nintedanib, are able to turn off myofibroblasts.
"That's totally in keeping with the fact that they do slow the progression, but they don't halt or reverse disease," said Fortier.
Fortier hopes the discovery that this pathway reverses fibrosis leads to exploration of additional brakes on fibrosis.
"So much work on fibrosis has focused on how we can prevent it, but when a patient presents to my clinic with a dry cough, shortness of breath, and low oxygen as a result of underlying IPF, the scarring is already present. Of course, we'd love a way to prevent the scarring from getting worse, but the Holy Grail is to reverse it."
Disclaimer: This post has been auto-published from an agency feed without any modifications to the text and has not been reviewed by an editor